A Retrospective Real-World Study of Dapagliflozin Versus Other Oral Antidiabetic Drugs Added to Metformin in Patients with Type 2 DiabetesByHuan Huang, PhD,Kelly F. Bell, PharmD, MSPhr,Ray Gani, PhD,Cathy W. Tugwell, RN, BSN,James M. Eudicone, MS, MBA,Michelle R. Krukas-Hampel, MAApril 14th 2018
Eligibility Varies Among the 4 Sodium-Glucose Cotransporter-2 Inhibitor Cardiovascular Trials: Implications for the General Type 2 Diabetes US PopulationByEric T. Wittbrodt, PharmD, MPH,James M. Eudicone, MS, MBA,Kelly F. Bell, PharmD, MSPhr,Devin M. Enhoffer, PharmD,Keith Latham, PharmD,Jennifer B. Green, MDApril 14th 2018
Generalizability of Glucagon-Like Peptide-1 Receptor Agonist Cardiovascular Outcome Trials Enrollment Criteria to the US Type 2 Diabetes PopulationByEric T. Wittbrodt, PharmD, MPH,James M. Eudicone, MS, MBA,Kelly F. Bell, PharmD, MSPhr,Devin M. Enhoffer, PharmD,Keith Latham, PharmD,Jennifer B. Green, MDApril 14th 2018
Comparison of Low-Dose Liraglutide Use Versus Other GLP-1 Receptor Agonists in Patients Without Type 2 DiabetesByEric T. Wittbrodt, PharmD, MPH,James M. Eudicone, MS, MBA,Sepehr Farahbakhshian, MS,Carrie McAdam-Marx, PhD, MSCI, RPhApril 14th 2018
Real World Evidence in Type 2 Diabetes: Focus on SGLT2 Inhibitors and GLP-1 Receptor Agonist Participating Faculty ByApril 14th 2018
